viewArix Bioscience PLC

Arix Bioscience portfolio company Autolus Therapeutics raises US$109mln

The total of US$109mln is more than Autolus had originally set out to raise from the market

cancer cells
Arix’s 7.5% stake is currently valued at US$94mln (£72mln)

Autolus Therapeutics PLC (NASDAQ:AUTL), a portfolio company of biotech investor Arix Bioscience PLC (LON:ARIX), has raised more than expected from its recent public offering.

Autolus, which is developing next-gen cancer immunotherapies, had originally set out to raise US$100.8mln through the issue of 4.2mln American Depositary Shares (ADS) at US$24.00 apiece.

READ: Arix to invest another US$5mln in Autolus

But it ended up issuing 4.83mln ADS at the same price to raise US$109.0mln.

As part of the offering, Arix agreed to invest US$5mln, keeping its stake in Autolus at 7.5%, which is currently valued at US$94mln (£72mln).

Speaking last week, Arix chief executive Joe Anderson said: “Our investment in Autolus demonstrates our strategy to build world-leading biotech companies through the provision of flexible, long term capital.

“We believe Autolus is at the forefront of a revolution in cancer treatment and that its innovative approach to T-cell programming has the potential to offer life-changing therapies for patients.”

Quick facts: Arix Bioscience PLC

Price: 111.5 GBX

Market: LSE
Market Cap: £151.14 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...



Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19

2 min read